Acorda Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Acorda Therapeutics, Inc.
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.
The bamlanivimab/etesevimab combo, filed for US emergency authorization in November, shows ability to reduce risk of hospitalization or death in COVID-19 patients. Lilly also sees prevention role for bamlanivimab.
Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.
The fourth quarter proved to be challenging for Novartis, with its dermatology, ophthalmology and oncology products – and Zolgensma – feeling the impact of COVID-19 lockdowns. The company is hoping for much better things in the second part of 2021.
- Drug Delivery
- Other Names / Subsidiaries
- Neuronex, Inc.
- Civitas Therapeutics
- Biotie Therapies Corp.
- Elbion GmbH
- Synosia Therapeutics, Inc.